This bill directs the Department of Veterans Affairs to create a network of designated medical facilities focused on delivering, researching, and training clinicians in so‑called innovative therapies for a set of mental health, neurologic, and pain conditions affecting veterans. It establishes selection criteria for those centers, a review mechanism to vet proposals, requirements for academic affiliations and veteran advisory input, and an annual reporting obligation to Congress.
The measure authorizes dedicated appropriations to support research and education activities at the centers and gives the VA tools to build shared infrastructure (consortia and a national data repository) intended to scale diagnosis, care, and training across the VA medical system. For compliance officers and program leaders, the bill creates new operational responsibilities around program development, data collection, and inter-facility coordination.
At a Glance
What It Does
The bill requires the Secretary of Veterans Affairs, on the Under Secretary for Health’s recommendation, to designate medical facilities as innovative therapies centers of excellence and to establish and operate them subject to appropriations. It creates a designated peer review panel to assess proposals, mandates annual reporting to congressional veterans’ committees, and authorizes annual appropriations to support center research and education.
Who It Affects
Affected parties include VA medical facilities chosen as centers, the Under Secretary for Health (responsible for recommendations and allocations), affiliated accredited schools (medicine, psychiatry, social work), VA researchers and clinicians who will deliver or study these therapies, and veterans seeking treatment for listed conditions.
Why It Matters
The bill formalizes VA endorsement of a set of therapies now described as 'innovative' by creating centralized clinical and research hubs, likely concentrating expertise and data collection inside the VA. That centralization can accelerate clinician training and evidence development but also shifts operational and budgetary obligations to VA leadership and selected facilities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new statutory section directing the VA to stand up centers of excellence dedicated to 'innovative therapies'—a label the statute attaches to a list of specified substances and to any therapies the Under Secretary later designates. VA must set up and operate these centers at designated Department medical facilities, and the statute requires those centers to serve three functions: clinical care, research, and education/training for residents and clinicians.
Designation is competitive: proposals from VA facilities will be reviewed by a peer review panel of experts in innovative therapies, which reports on the scientific and clinical merit of proposals. The bill sets a menu of institutional capabilities the VA must look for—formal affiliations with an accredited medical school, psychiatry program, and school of social work; the ability to attract creative researchers; an advisory committee that includes veterans; evaluation capacity; integration with other VA facilities for education and clinical activity; the ability to build provider consortia to extend access; and capacity to create a national data repository for services provided.Operationally, the statute requires the Under Secretary to provide an annual report to the congressional Veterans’ Affairs committees that summarizes center activities, key findings, and recommendations to improve delivery.
Funding is addressed directly: the bill authorizes a specified annual appropriation for center research and education and directs the Under Secretary to allocate additional amounts from existing medical services and research accounts as appropriate. The statute also defines both the covered conditions (for example, PTSD, depression, chronic pain, Parkinson’s, substance use disorder, bipolar disorder, anxiety) and the therapies currently included (for example, psilocybin, ketamine, ibogaine, MDMA analogue listed by chemical name, and 5‑MeO‑DMT), while giving the Under Secretary authority to add others.A notable procedural detail: the peer review panel is explicitly not subject to the Federal Advisory Committee Act, and initial terms are staggered so members serve two- or three-year terms; later appointments are capped at two years.
The bill also requires geographic distribution among designated centers, signaling intent to avoid total regional concentration of services.
The Five Things You Need to Know
The Secretary must designate not fewer than five VA medical facilities as locations for innovative therapies centers of excellence, based on recommendations from the Under Secretary for Health and peer review.
A peer review panel of experts in innovative therapies will assess proposals’ scientific and clinical merit; the panel is exempted from chapter 10 of title 5 (FACA) and uses staggered two‑ and three‑year initial terms.
The statute defines a list of covered conditions (including PTSD, depression, chronic pain, Parkinson’s disease, bipolar disorder, anxiety, and substance use disorder) and enumerates specific 'innovative therapies' such as psilocybin, ketamine, ibogaine, 5‑MeO‑DMT, and a methylenedioxy‑methamphetamine derivative.
The bill authorizes $30 million per fiscal year specifically to support research and education activities at the centers, and it permits the Under Secretary to reallocate additional amounts from VA medical services and medical and prosthetics research accounts.
Designated centers must hold formal affiliations with accredited medical, psychiatry, and social work schools, form veteran-inclusive advisory committees, develop provider consortia to expand access across VA facilities, and create a national repository for data on services delivered.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Act title
Gives the statute the short name 'Innovative Therapies Centers of Excellence Act.' This is purely stylistic but ensures later references use the Act’s formal name.
Establishment and designation of centers
The statute requires the Secretary, on the Under Secretary for Health’s recommendation, to designate locations within the Department as centers of excellence and to establish and operate them subject to appropriations. Practically, this converts a policy choice into a statutory duty to create designated hubs when funds are available and gives the Under Secretary a central recommending role.
Geographic distribution requirement
The statute mandates that the chosen centers be distributed appropriately across geography. Although 'appropriate' is not strictly defined, the requirement implies VA must balance concentration of expertise with regional access—an administrative judgment the Under Secretary will make and defend.
Competitive standards and institutional requirements
A facility cannot be designated unless a peer review panel finds its proposal meets the highest competitive standards of scientific and clinical merit. The law also lists institutional prerequisites: affiliations with an accredited medical school, psychiatry program, and social work school; the ability to attract inventive researchers; veteran-inclusive advisory committees; evaluation capacity; systemwide coordination for education, clinical, and research activities; capacity to build provider consortia to extend access; and ability to develop a national data repository. Those are concrete checklist items VA reviewers will apply when assessing proposals.
Expert review panel and membership rules
The Under Secretary must establish a panel of experts in innovative therapies to evaluate proposals and report on their relative scientific and clinical merit. Membership terms are capped, with initial staggered appointments; the panel is explicitly exempted from the Federal Advisory Committee Act, which limits public meeting and record requirements and concentrates control inside VA—accelerating decisions but reducing formal external oversight.
Congressional reporting requirements
The Under Secretary must submit a first report not later than two years after enactment and annual reports thereafter to the Senate and House Veterans’ Affairs Committees. Reports must summarize activities, identify key findings, recommend improvements for delivery, and may include other matters the Under Secretary finds relevant—building an ongoing congressional oversight mechanism and an evidence base.
Authorization and statutory definitions
The bill authorizes $30 million per fiscal year to support research and education at the centers and authorizes the Under Secretary to allocate additional funds from existing VA medical services and medical and prosthetics research accounts. The definitions subsection enumerates 'covered conditions' and specific 'innovative therapies' (by chemical or common name) and gives the Under Secretary authority to add conditions or therapies by designation—creating a statutory floor while preserving executive discretion to expand scope.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with treatment‑resistant mental health or neurologic conditions — The statute targets conditions such as PTSD, chronic pain, depression, Parkinson’s, and substance use disorder and creates specialized treatment and research access within VA for those veterans.
- VA researchers and clinicians at designated centers — They gain concentrated funding streams, research infrastructure, and formal affiliations that can accelerate trials, training, and publishing opportunities.
- Affiliated academic programs (medical schools, psychiatry and social work schools) — Formal partnerships create clinical training slots, research collaborations, and curricula tied to innovative therapies.
- Veteran advocacy and advisory participants — The required veteran-inclusive advisory committees give veterans structured input into center policy and program design, potentially shaping service delivery.
- VA system administrators — A national repository and integrated network create a single data resource that can inform policy, quality metrics, and systemwide scaling of practices.
Who Bears the Cost
- Department of Veterans Affairs budget holders — The bill authorizes $30 million per year and permits reallocation from VA medical services and research accounts; sustaining and scaling the program will rely on VA budget decisions and may crowd out other priorities.
- Selected VA facilities — Designated centers must meet institutional requirements (affiliations, advisory committees, evaluation capacity), which will require administrative, staffing, and capital investments at a facility level.
- Under Secretary for Health and VA operations teams — They carry the administrative burden of running the competitive process, managing peer review, allocating funds, producing annual reports, and overseeing consortia and the national repository.
- Non‑designated VA facilities and regional networks — Facilities not selected may face slower access to center resources and will need to participate in consortia to maintain access, potentially increasing coordination costs.
- Peer review panel participants and VA program staff — Running expedited, high‑stakes reviews and coordination without FACA protections or formal external transparency will place procedural and reputational responsibilities on panel members and staff.
Key Issues
The Core Tension
The central dilemma is whether to accelerate veteran access to promising but still‑evolving therapies by concentrating expertise and funding in designated VA hubs, or to prioritize rigorous, transparent evidence development and cautious, distributed rollout—each choice advances veteran care in different ways but creates trade‑offs among access, safety, equity, and legal/regulatory compliance.
The statute blends clinical service, research, and training under one label—'innovative therapies'—and leaves critical choices to the Under Secretary. That creates flexibility (the Under Secretary can add therapies and conditions) but also raises regulatory and implementation questions: several therapies listed are controlled substances under federal law or remain in shifting FDA regulatory pathways, so the VA will need compliance plans addressing schedules, investigational use, and state vs federal enforcement.
The requirement for institutional affiliations, consortia, and a national repository pushes centers toward resource‑intensive infrastructure; $30 million annually is a clear line item but may be insufficient to support multi‑site clinical trials, large‑scale training, and data systems without further appropriations or internal reallocations.
Procedurally, exempting the peer review panel from the Federal Advisory Committee Act speeds internal deliberations but reduces external transparency and public access to deliberative records. The bill also directs geographic distribution without a statutory definition, leaving room for internal negotiation and potential political influence over where centers land.
Finally, the law combines research and clinical care responsibilities: that blurs FDA investigational pathways versus standard-of-care delivery and raises questions about consent, off‑label care, liability, and how the VA will balance compassionate access with rigorous evidence development.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.